TipRanks
Advertisement
Advertisement

AKESF Stock Latest News

Summit Therapeutics Stock (SMMT) Rallies on Positive Clinical Trial Results
Market NewsSummit Therapeutics Stock (SMMT) Rallies on Positive Clinical Trial Results
1M ago
SMMT
Akeso’s Ivonescimab Tops Pembrolizumab in Key Lung Cancer Survival Trial
PremiumCompany Announcements
Akeso’s Ivonescimab Tops Pembrolizumab in Key Lung Cancer Survival Trial
1M ago
Akeso Narrows Interim Loss as Revenue Jumps Nearly 28%
PremiumCompany Announcements
Akeso Narrows Interim Loss as Revenue Jumps Nearly 28%
1M ago
Akeso Initiated at Buy on Breakthrough Ivonescimab Phase 3 BTC Data and Multibillion-Dollar Upside Potential
PremiumRatings
Akeso Initiated at Buy on Breakthrough Ivonescimab Phase 3 BTC Data and Multibillion-Dollar Upside Potential
1M ago
Akeso’s Ivonescimab Delivers Phase III Survival Gain in Biliary Tract Cancer
PremiumCompany Announcements
Akeso’s Ivonescimab Delivers Phase III Survival Gain in Biliary Tract Cancer
1M ago
Akeso Schedules Board Meeting to Approve 2026 Interim Results
PremiumCompany AnnouncementsAkeso Schedules Board Meeting to Approve 2026 Interim Results
2M ago
Summit says Akeso receives marketing authorization in China for ivonescimab
Premium
The Fly
Summit says Akeso receives marketing authorization in China for ivonescimab
2M ago
SMMT
Akeso Wins Third NMPA Nod for Ivonescimab in Advanced Lung Cancer
Premium
Company Announcements
Akeso Wins Third NMPA Nod for Ivonescimab in Advanced Lung Cancer
2M ago
Akeso Grants New Share Options to Boost Long-Term Incentives
PremiumCompany Announcements
Akeso Grants New Share Options to Boost Long-Term Incentives
2M ago
Akeso Shareholders Approve All Resolutions at 2026 AGM, Renewing Board Mandates and Capital Powers
PremiumCompany Announcements
Akeso Shareholders Approve All Resolutions at 2026 AGM, Renewing Board Mandates and Capital Powers
3M ago
Akeso Wins China NMPA Approval for IL-17 Antibody Gumokimab in Psoriasis
PremiumCompany Announcements
Akeso Wins China NMPA Approval for IL-17 Antibody Gumokimab in Psoriasis
4M ago
Akeso Launches HK$200 Million Share Purchase as Leadership Boosts Stakes
PremiumCompany Announcements
Akeso Launches HK$200 Million Share Purchase as Leadership Boosts Stakes
4M ago
Akeso Sets 2026 AGM to Approve Accounts, Board Slate and Capital-Issuance Mandate
PremiumCompany AnnouncementsAkeso Sets 2026 AGM to Approve Accounts, Board Slate and Capital-Issuance Mandate
4M ago
Akeso’s ivonescimab trial at ASCO plenary signals potential new lung cancer standard
Premium
Company Announcements
Akeso’s ivonescimab trial at ASCO plenary signals potential new lung cancer standard
4M ago
Akeso: Robust FY25 Execution and Late‑Stage Oncology Pipeline Drive Upside and Higher Target Price
Premium
Ratings
Akeso: Robust FY25 Execution and Late‑Stage Oncology Pipeline Drive Upside and Higher Target Price
6M ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
6M ago
RADX
SMMT
Summit Therapeutics to present multiple ivonescimab data sets at ELCC 2026
PremiumThe Fly
Summit Therapeutics to present multiple ivonescimab data sets at ELCC 2026
6M ago
SMMT
Akeso Boosts Revenue and R&D While Trimming Adjusted EBITDA Loss in 2025
PremiumCompany Announcements
Akeso Boosts Revenue and R&D While Trimming Adjusted EBITDA Loss in 2025
6M ago
Akeso Schedules Board Meeting to Approve 2025 Annual Results
PremiumCompany Announcements
Akeso Schedules Board Meeting to Approve 2025 Annual Results
7M ago
Akeso Grants JumpCan Exclusive Mainland China Rights to Cholesterol Drug 伊喜寧®
PremiumCompany AnnouncementsAkeso Grants JumpCan Exclusive Mainland China Rights to Cholesterol Drug 伊喜寧®
8M ago
Akeso Details Long-Term MAb Contract Manufacturing and Demand Assumptions
Premium
Company Announcements
Akeso Details Long-Term MAb Contract Manufacturing and Demand Assumptions
8M ago
Akeso announces NMPA acceptance of second NDA for gumokimab
Premium
The Fly
Akeso announces NMPA acceptance of second NDA for gumokimab
9M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >